Clin2
NCT07024160Likely a fitRecruiting

First-in-human study of MT1011 injection in healthy volunteers

Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation

Part of Blood & lymphatic clinical trials.

This trial tests a new medicine called MT1011 given as an injection. Researchers want to see how safe it is and how the body handles it. Healthy people can join to help find the right dose for future studies.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
40 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You must be between 18 and 45 years old.
  • You must be generally healthy, with no major medical problems.
  • Men must weigh at least 50 kg (110 lbs) and women at least 45 kg (99 lbs).
  • Your body mass index (BMI) must be between 18.5 and 26.0.
  • You must not be pregnant, breastfeeding, or planning to become pregnant or donate sperm or eggs during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07419698Recruiting· Phase 1
Safety study of JMT206 injection in healthy volunteers

This early-stage trial tests a new medicine called JMT206 in healthy people to see if it is safe and how the body handles it. Healthy volunteers, ages 18 to 60, are needed to help researchers learn about the drug's effects and how it moves through the body.

Beijing, Beijing Municipality
NCT07190716Not yet recruiting· Phase 1
Safety study of GR2301 injection in healthy volunteers

This trial tests a new injection called GR2301 to see if it is safe in healthy people. Volunteers will help researchers understand any side effects before the drug is given to patients with a disease.

Beijing, Beijing Municipality
NCT06533358Recruiting· Phase 2
Testing MT1002 for heart attack patients getting a stent

This study tests an investigational medicine called MT1002 in people who have had a heart attack and are about to get a stent (PCI). The goal is to see if MT1002 helps prevent further heart problems.

Beijing, Beijing Municipality
NCT06324604Recruiting· Phase 1
Safety study of MTX-101 in healthy adults

This trial tests a new drug called MTX-101 in healthy volunteers to see if it is safe and how the body processes it. It helps determine the right dose before testing in patients with certain conditions.

Heidelberg, Victoria
NCT07584876Recruiting· Phase 1
Safety study of a new blood clotting medicine in healthy adults

This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.

Perth, Western Australia
NCT07219368Recruiting· Phase 1
Testing a new drug (MT-201) safety in healthy adults

This trial tests a new medicine called MT-201 to see if it is safe and how the body handles it. It is for healthy volunteers aged 19 to 55 who are willing to follow study rules.

San Diego, California

Hear when a new Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.